Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature

被引：0

作者：

Koutras, A. K. ^{[1
]}

Talampuka, G. ^{[1
]}

Pagoni, N. ^{[2
]}

Thomopoulos, K. C. ^{[2
]}

Kalliolias, G. ^{[1
]}

Kalogeropoulou, C. ^{[3
]}

Kalofonos, H. P. ^{[1
]}

机构：

[1] Univ Hosp, Patras Med Sch, Dept Med, Div Oncol, Rion 26504, Greece

[2] Univ Hosp, Patras Med Sch, Dept Med, Div Gastroenterol, Rion 26504, Greece

[3] Univ Hosp, Patras Med Sch, Dept Radiol, Rion 26504, Greece

来源：

JOURNAL OF BUON | 2007年 / 12卷 / 02期

关键词：

capecitabine; cholangiocarcinoma; metastatic; pretreated;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cholangiocarcinoma is one of the most aggressive malignancies. Patients with advanced or metastatic disease have a particularly dismal prognosis. The role of chemotherapy remains a matter of debate. A number of recent trials have shown that capecitabine in combination with other agents seems to be active as first-line treatment in advanced biliary cancer. Clinical data regarding the activity of capecitabine in pretreated patients are limited. metastatic cholangiocarcinoma who developed stabilization of the disease for 7 months following chemotherapy with capecitabine. The patient had previously received 2 lines of chemotherapy. Capecitabine was tolerated fairly well without serious adverse events. We consider this observation to be important given the absence of active, non-surgical treatments in unresectable tumors.

引用

页码：281 / 283

页数：3

共 13 条

[1]

DAVIS HL, 1974, CANCER, V33, P193, DOI 10.1002/1097-0142(197401)33:1<193::AID-CNCR2820330128>3.0.CO

[2]

2-S

[3]

FALKSON G, 1984, CANCER, V54, P965, DOI 10.1002/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO

[4]

2-X

[5]

Fong Y, 2001, CANC PRINCIPLES PRAC, P1162

[6] Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: Results of a multicenter phase II study [J].

Gebbia, V ;

Giuliani, F ;

Maiello, E ;

Colucci, G ;

Verderame, F ;

Borsellino, N ;

Mauceri, G ;

Caruso, M ;

Tirrito, ML ;

Valdesi, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) :4089-4091

[7] Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer [J].

Glimelius, B ;

Hoffman, K ;

Sjoden, PO ;

Jacobsson, G ;

Sellstrom, H ;

Enander, LK ;

Linne, T ;

Svensson, C .

ANNALS OF ONCOLOGY, 1996, 7 (06) :593-600

[8] The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature [J].

Hejna, M ;

Pruckmayer, M ;

Raderer, M .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) :977-986

[9] Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer [J].

Kim, TW ;

Chang, HM ;

Kang, HJ ;

Lee, JR ;

Ryu, MH ;

Ahn, JH ;

Kim, JH ;

Lee, JS ;

Kang, YK .

ANNALS OF ONCOLOGY, 2003, 14 (07) :1115-1120

[10] Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial [J].

Knox, JJ ;

Hedley, D ;

Oza, A ;

Feld, R ;

Sin, LL ;

Chen, E ;

Nematollahi, M ;

Pond, GR ;

Zhang, J ;

Moore, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2332-2338

← 1 2 →